Our Partnership with AGTC
In April 2015, Applied Genetic Technologies Corporation (Nasdaq: AGTC) and 4D Molecular Therapeutics signed a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need. As part of the agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors. Sue Washer, President and CEO of AGTC, noted, “We are excited to partner with 4DMT to accelerate development of novel AAV-based gene therapies to treat rare eye diseases. We expect that our combined expertise and our complementary proprietary technology and discovery platforms, will enable us to advance new treatments to market for patients with serious inherited ocular conditions who have few currently available therapeutic options.” 4DMT believes that great synergies will result from combining our AAV-based gene therapy platform discovery with AGTC’s expertise in ocular gene therapy development. Together we can develop highly optimized and customized gene therapeutics, and this licensing agreement further underscores our commitment to create a robust product pipeline with our partners.
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC’s lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also pursuing pre-clinical development of treatments for wet AMD using the company’s experience in ophthalmology to expand into disease indications with larger markets.